Cargando…
Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study
An increasing number of patients with cancer are being treated with immune checkpoint inhibitors. Consequently, the incidence of immune checkpoint inhibitor-related myocarditis has been increasing. Nonetheless, the diagnostic criteria for the immune checkpoint inhibitor-related myocarditis have not...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665386/ https://www.ncbi.nlm.nih.gov/pubmed/36378654 http://dx.doi.org/10.1371/journal.pone.0275865 |
_version_ | 1784831275717099520 |
---|---|
author | Nishikawa, Tatsuya Inoue, Takako Otsuka, Tomoyuki Kuno, Ikumi Kukita, Yoji Nakamura, Harumi Ikeda, Yoshihiko Yasui, Taku Shioyama, Wataru Oka, Toru Honma, Keiichirou Hatakeyama, Kinta Miyata, Hiroshi Isei, Taiki Ishihara, Ryu Kumagai, Toru Nishimura, Kazuo Fujita, Masashi |
author_facet | Nishikawa, Tatsuya Inoue, Takako Otsuka, Tomoyuki Kuno, Ikumi Kukita, Yoji Nakamura, Harumi Ikeda, Yoshihiko Yasui, Taku Shioyama, Wataru Oka, Toru Honma, Keiichirou Hatakeyama, Kinta Miyata, Hiroshi Isei, Taiki Ishihara, Ryu Kumagai, Toru Nishimura, Kazuo Fujita, Masashi |
author_sort | Nishikawa, Tatsuya |
collection | PubMed |
description | An increasing number of patients with cancer are being treated with immune checkpoint inhibitors. Consequently, the incidence of immune checkpoint inhibitor-related myocarditis has been increasing. Nonetheless, the diagnostic criteria for the immune checkpoint inhibitor-related myocarditis have not been sufficiently established. Therefore, the real-world incidence or prevalence of immune checkpoint inhibitor-related myocardial damage remains unknown. This was a single-center cohort study that included 100 patients admitted for immune checkpoint inhibitor therapy for any type of cancer. The patients underwent monthly measurement of cardiac troponin I and N-terminal pro-brain natriuretic peptide levels with electrocardiography. Additionally, echocardiography was performed every 3 months. Our protocol was continued until 6 months after the initiation of immune checkpoint inhibitors. We defined immune checkpoint inhibitor-related myocardial damage as an increase in cardiac troponin I levels by >0.026 ng/mL and/or a decrease in the left ventricular ejection fraction by >10% to <53% on echocardiography. The mean patient age was 64 years; 71% were men. The most commonly used immune checkpoint inhibitor was nivolumab (47%), followed by pembrolizumab (29%). Overall, 5% of patients received combination therapy. Among 100 patients, 10 (10%) were diagnosed with immune checkpoint inhibitor-related myocardial damage. Among them, five patients underwent endomyocardial biopsy. Of these patients, four were histopathologically observed to have lymphocyte infiltration in their myocardium. In conclusion, serial cardiac troponin I measurement during immune checkpoint inhibitor treatment could help detect early-phase myocardial damage. The prevalence of myocardial damage was much higher than previously expected. |
format | Online Article Text |
id | pubmed-9665386 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-96653862022-11-15 Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study Nishikawa, Tatsuya Inoue, Takako Otsuka, Tomoyuki Kuno, Ikumi Kukita, Yoji Nakamura, Harumi Ikeda, Yoshihiko Yasui, Taku Shioyama, Wataru Oka, Toru Honma, Keiichirou Hatakeyama, Kinta Miyata, Hiroshi Isei, Taiki Ishihara, Ryu Kumagai, Toru Nishimura, Kazuo Fujita, Masashi PLoS One Research Article An increasing number of patients with cancer are being treated with immune checkpoint inhibitors. Consequently, the incidence of immune checkpoint inhibitor-related myocarditis has been increasing. Nonetheless, the diagnostic criteria for the immune checkpoint inhibitor-related myocarditis have not been sufficiently established. Therefore, the real-world incidence or prevalence of immune checkpoint inhibitor-related myocardial damage remains unknown. This was a single-center cohort study that included 100 patients admitted for immune checkpoint inhibitor therapy for any type of cancer. The patients underwent monthly measurement of cardiac troponin I and N-terminal pro-brain natriuretic peptide levels with electrocardiography. Additionally, echocardiography was performed every 3 months. Our protocol was continued until 6 months after the initiation of immune checkpoint inhibitors. We defined immune checkpoint inhibitor-related myocardial damage as an increase in cardiac troponin I levels by >0.026 ng/mL and/or a decrease in the left ventricular ejection fraction by >10% to <53% on echocardiography. The mean patient age was 64 years; 71% were men. The most commonly used immune checkpoint inhibitor was nivolumab (47%), followed by pembrolizumab (29%). Overall, 5% of patients received combination therapy. Among 100 patients, 10 (10%) were diagnosed with immune checkpoint inhibitor-related myocardial damage. Among them, five patients underwent endomyocardial biopsy. Of these patients, four were histopathologically observed to have lymphocyte infiltration in their myocardium. In conclusion, serial cardiac troponin I measurement during immune checkpoint inhibitor treatment could help detect early-phase myocardial damage. The prevalence of myocardial damage was much higher than previously expected. Public Library of Science 2022-11-15 /pmc/articles/PMC9665386/ /pubmed/36378654 http://dx.doi.org/10.1371/journal.pone.0275865 Text en © 2022 Nishikawa et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Nishikawa, Tatsuya Inoue, Takako Otsuka, Tomoyuki Kuno, Ikumi Kukita, Yoji Nakamura, Harumi Ikeda, Yoshihiko Yasui, Taku Shioyama, Wataru Oka, Toru Honma, Keiichirou Hatakeyama, Kinta Miyata, Hiroshi Isei, Taiki Ishihara, Ryu Kumagai, Toru Nishimura, Kazuo Fujita, Masashi Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study |
title | Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study |
title_full | Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study |
title_fullStr | Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study |
title_full_unstemmed | Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study |
title_short | Prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: A prospective observational study |
title_sort | prevalence and characteristics of immune checkpoint inhibitor-related myocardial damage: a prospective observational study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9665386/ https://www.ncbi.nlm.nih.gov/pubmed/36378654 http://dx.doi.org/10.1371/journal.pone.0275865 |
work_keys_str_mv | AT nishikawatatsuya prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT inouetakako prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT otsukatomoyuki prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT kunoikumi prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT kukitayoji prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT nakamuraharumi prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT ikedayoshihiko prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT yasuitaku prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT shioyamawataru prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT okatoru prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT honmakeiichirou prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT hatakeyamakinta prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT miyatahiroshi prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT iseitaiki prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT ishihararyu prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT kumagaitoru prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT nishimurakazuo prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy AT fujitamasashi prevalenceandcharacteristicsofimmunecheckpointinhibitorrelatedmyocardialdamageaprospectiveobservationalstudy |